Addison’s Disease Market Share

Addison’s Disease Market Overview:

Addison’s Disease Market Size was valued at USD 2.21 Billion in 2023. The Addison’s Disease industry is projected to grow from USD 2.34 Billion in 2024 to USD 5.35 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.84% during the forecast period (2024 - 2032). Addison's disease is a condition in which the body generates insufficient levels of certain hormones made by the adrenal glands. The adrenal glands generate too little cortisol and typically insufficient quantities of aldosterone in people with Addison's disease.

Adrenal insufficiency is another name for it. Addison's disease may afflict people of all ages and impact both men and women. The market is predicted to rise due to reasons such as the rising prevalence of Addison's disease, increased awareness of the condition, and rising healthcare spending. Lack of knowledge and difficulty to detect the condition in its early stages, on the other hand, may limit market growth throughout the projection period.

Segmentation

The market, by end user, has been segmented into hospitals & clinics, diagnostic laboratories, and other end users.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 

The Addison’s disease market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key Players

• Pfizer Inc


• Boehringer Ingelheim International GmbH


• Shire


• Tocris Bioscience


• GlaxoSmithKline plc


• Merck KGaA


• Lupin Pharmaceuticals, Inc


• Abbott


• Amgen Limited & Amgen Ireland Limited


• Bayer AG


• Biogen


• Eli Lilly and Company


• Novartis AG


• Diurnal


• Switzer Life science Pvt. Ltd

Regional Market Summary

Global Addison’s Disease Market Share (%), by Region, 2017

Source: Centers for Disease Control and Prevention (CDC), Eurostat, White Papers, Company Presentations, Annual Reports

Geographically, the Americas is anticipated to dominate the global Addison's disease market owing to a well-developed healthcare sector and the rising prevalence of the disease. According to a report published by the Centers Medicare and Medicaid Services in April 2018, National Healthcare Expenditure grew by 4.3% to USD 3.3 trillion in 2016 from the previous year.

Europe is expected to hold the second largest position in the global market. The market growth in this region is attributed to the increasing number of Addison’s disease cases and the developed healthcare infrastructure. According to the World Health Organization, Germany spent USD 5182 per capita on healthcare.

The Addison’s disease market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be the fastest growing region owing to the increasing prevalence of Addison’s disease and growing awareness of the same. According to the World Bank Group, India spent 3.89% of its GDP on health in 2015.

The Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.Recent Development

Lupin Ltd (Lupin) is a pharmaceutical company that produces and markets generic and branded pharmaceuticals, as well as active pharmaceutical ingredients (APIs). Cardiovascular, diabetes etc are all part of the company's product range. Oral, ophthalmic, dermatological, and inhalation product research are key priorities for the organization. The company's operations are reported under a single segment, Pharmaceuticals. Formulations, active pharmaceutical ingredients (APIs), generic formulations, and biotechnology products are all part of Lupin's business.

In August 2015, Amgen, a biotechnology corporation located in the United States, launched its significantly enlarged production plant in Dun Laoghaire, Ireland. The $300 million expansion expanded manufacturing facilities to the existing factory, enhancing its capabilities and positioning it as a major hub for Amgen's global operations. The move was part of Amgen's long-term plan to manufacture all of its pharmaceuticals at the Dun Laoghaire facility, ensuring a steady supply of Amgen's medicines for severely sick patients across the world.

Global Addison’s Disease Market, by Diagnosis

• Laboratory Tests
  
  
  
  • Blood Tests
  
  
  • ACTH Stimulation Tests
  
  
  • Insulin-Induced Hypoglycemia Test
  
  
  • Other Tests
  
  
  
  

• Imaging Tests
  
  
  
  • Chest Radiography
  
  
  • CT Scan
  
  
  
  

Global Addison’s Disease Market, by Treatment

• Oral Corticosteroid


• Corticosteroid Injections

Global Addison’s Disease Market, by End User

• Hospitals and Clinics


• Diagnostic Laboratories


• Other End Users

Global Addison’s Disease Market, by Region

• Americas
  
  
  
  • North America
    
    
    
    • US
    
    
    • Canada
    
    
    
    
  
  
  • South America
  
  
  
  

• Europe
  
  
  
  • Western Europe
    
    
    
    • Germany
    
    
    • France
    
    
    • Italy
    
    
    • Spain
    
    
    • UK
    
    
    • Rest of Western Europe
    
    
    
    
  
  
  • Eastern Europe
  
  
  
  

• Asia-Pacific
  
  
  
  • Japan
  
  
  • China
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Rest of Asia-Pacific
  
  
  
  

• Middle East & Africa
  
  
  
  • Middle East
  
  
  • Africa
  
  
  
  

Global Addison’s Disease Market, by Key Players

• Pfizer Inc.


• Boehringer Ingelheim International GmbH


• Shire


• Tocris Bioscience


• GlaxoSmithKline Plc


• Merck KGaA


• Lupin Pharmaceuticals, Inc.


• Abbott


• Amgen Limited & Amgen Ireland Limited